LSD

A new pilot study suggests that taking small, sub-perceptual doses of LSD could temporarily boost feelings of creativity and social connection in individuals with major depression. However, researchers caution that placebo-controlled trials are still needed.

Recent research is dampening the hype around psychedelic therapy. By adjusting for how clinical trials are designed, scientists found that drugs like LSD and psilocybin offer similar depression relief to traditional antidepressants, rather than vastly superior results.

A double-blind trial suggests that microdosing the psychedelic drug LSD can reverse blunted neurological responses to emotional rewards, potentially offering targeted biological interventions for individuals struggling with mild to moderate depression.

Scientists have found evidence that LSD inhibits status epilepticus and mortality in mice. The preliminary research suggests the drug works by desynchronizing brain activity.

While clinical trials investigate psychedelics for addiction treatment, new population-level research indicates that LSD is associated with reduced alcohol use disorder in naturalistic settings.

A new meta-analysis suggests LSD has a small but significant positive effect on substance use disorders. The review found inconclusive evidence for its use in treating anxiety or depression, highlighting a split in its therapeutic potential.

A groundbreaking study has revealed that classical psychedelics affect far more than just serotonin. By mapping how 41 compounds interact with brain receptors, researchers challenge long-held assumptions and open new directions for psychedelic science and therapeutic development.

A new study introduces JRT, a modified version of LSD that promotes brain cell growth without triggering hallucinations. Researchers say this non-hallucinogenic compound could offer safer treatment options for schizophrenia and related brain disorders where psychedelics are typically contraindicated.

A new brain imaging study finds LSD alters brain connectivity in unique ways, setting it apart from MDMA and amphetamine despite some shared effects.

Microdosing LSD has no clear benefit for ADHD, according to a new placebo-controlled clinical trial published in JAMA Psychiatry.

A study of British adults found that those who had used psychedelics were 25% less likely to report frequent bad headaches, adding to growing research on psychedelics’ potential medical benefits.

Recent research found that psychedelic-assisted therapy reduced depressive symptoms, with relaxation during sessions being the strongest predictor of improvement.

Psychedelics impair attention and decision-making during use but may boost creativity afterward. In contrast, MDMA primarily disrupts memory, with no lasting cognitive benefits—highlighting the complex, varied effects of these substances on the brain.

LSD alters brain activity and connectivity in key regions associated with pain processing, offering potential insights for pain management and the therapeutic use of psychedelics.

Microdosing LSD leads to participants sleeping 24 minutes longer and going to bed 25 minutes earlier, with an 8-minute increase in REM sleep, according to a recent study published in Translational Psychiatry.